OncoSec Medical Inc (ONCSQ)

[chickpea598]

Robert Andtbacka, MD, CM, is an associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine and a surgeon at Huntsman Cancer Institute. Dr. Andtbacka is recognized as a leader in intratumoral immunotherapies, and he was pivotal in the approval of Amgen’s oncolytica virus therapy, T-VEC, for melanoma.

Robert Andtbacka is now listed as a clinical and scientific advisor to Oncosec in their most updated investor download pack.

T-VEC scored big with Amgen buyout (worth 1 Billion) and Oncosec will follow after combo results this fall. Oncosec only has a 30 million market cap equal to the amount of cash they have and no debt.

oncosec.com/QR-Downloads/ONCS-Power-Point-Presentation_Web.pdf